We conducted a dose-escalation study with antithymocyte globulin (ATG) in patients undergoing unrelated donor bone marrow transplantation (URD-BMT). This study analyzes the results for 97 patients with chronic myelogenous leukemia (CML) in first chronic phase. Median age was 36 years (16-51). In all, 40 patients were transplanted within 2 years after diagnosis and 57 later during disease. ATG-S (Fresenius) 20-120 mg/kg body weight (b.w.) was given prior to transplantation. A total of 31 patients received less than 60 mg/kg b.w. and 66 patients received 60 mg/kg b.w. or more. All patients except one were grafted with bone marrow, and graftversus-host disease (GVHD) prophylaxis consisted of cyclosporin A and methotrexate. Graft failure did occur in one patient. Grade II-IV acute GVHD developed in 56.7% and extensive chronic GVHD in 11.3% of the patients. The relapse rate was 13.4%. With a median follow-up of 5.8 years (1.5-12.1), 5-year disease-free and overall survival for all patients were 56 and 66%, and for patients transplanted within 2 years of diagnosis it was 72 and 82%. A lower dose of ATG was a significant risk factor for poor outcome. In summary, URD-BMT remains an excellent treatment option for patients with early phase CML, if a sufficient amount of ATG is included in the preparative regimen.
The therapeutic options for patients with chronic myelogenous leukemia (CML) have changed dramatically during the past years. In particular, the introduction of the bcrabl-specific tyrosine kinase inhibitor imatinib mesylate (Gleevec s ) now offers a highly effective and well-tolerated oral therapy for CML patients. In contrast, allogeneic bone marrow transplantation (BMT), which is still the only curative treatment option, is associated with considerable mortality and morbidity. It, therefore, has been questioned if BMT should be offered to CML patients early during disease, especially if they lack an HLA-identical sibling donor. 1 Given the fact that, by the combined effort of the international registry networks, there are now 8 million HLA-typed volunteer donors available, the chance of finding a suitable donor in reasonable time for patients lacking an HLA-matched family member now exceeds 75%. Therefore, unrelated donar BMT (URD-BMT) is a realistic treatment option for a large group of patients in need. It was, however, reported to be associated with a higher risk of treatment failure. 2 In an analysis of more than 1400 patients with CML who underwent URD-BMT, graft failure and acute and chronic graft versus host disease (GVHD) were identified as the major obstacles of URD-BMT in these patients, whereas relapses occurred in only 6% of the patients. By contrast, transplant in chronic phase, within 1 year of diagnosis, younger recipient age, a cytomegalovirus (CMV) seronegative recipient and the lack of severe acute GVHD were independent factors for improved disease-free survival. 3 Although the routine use of high-resolution molecular typing of HLA class II and recently class I antigens already improved the incidence of GVHD to some extent, 4 further reducing the risks of graft failure and acute GVHD remain the major tasks in the setting of URD-BMT in CML patients. For this purpose, ex vivo T cell depletions of the marrow grafts have been performed in patients with CML, which led to a decreased incidence of acute GVHD. 5, 6 However, ex vivo T cell depletions carry the risk of higher relapse rates since the graft-versus-leukemia effect widely depends on the presence of donor T cells. 7, 8 An alternative strategy employs an in vivo T cell depletion with either monoclonal T cell-specific antibodies, like Campath1-H, 9 or with polyclonal antibodies, like antithymocyte globulin (ATG). 10, 11 During the years 1990-1997, we conducted a dose-escalation study with ATG for all the patients receiving marrow grafts from unrelated donors. This analysis evaluates the outcome of URD-BMT for patients with CML in first chronic phase with special respect to the dose of ATG applied during conditioning, and to the timing of transplantation.
Patients and methods

Patients
As analyzed by November 2002, 97 patients with CML in first chronic or accelerated phase received bone marrow grafts from unrelated volunteer donors between September 1990 and May 2001 after giving their informed consent to the procedure at the BMT unit of the medical clinic 3 of the University Hospital Grosshadern in Munich, Germany. Accelerated phase was defined either by the occurrence of B symptoms, or by increasing splenomegaly, or more than 20% basophils or eosinophils, or increasing numbers of leukocytes despite adequate therapy, or platelet counts of less than 100 000/ml or anemia with hemoglobin levels of less than 9 g/dl, or more than 10% blasts and promyelocytes in the peripheral blood or in bone marrow. Patients with advanced disease (blastic transformation or second chronic phase), with a follow-up of less than 18 months and patients receiving reduced intensity conditioning regimens were excluded from the study. Patient characteristics are summarized in Table 1 . Median patient age was 36 years (range 16 -51 years). The median time interval from initial diagnosis to transplantation was 30 months (range 6 -176 months).
Donor selection
Unrelated volunteer donors were preselected centrally at the central bone-marrow donor registry for Germany (ZKRD) in Ulm, Germany. They were matched by serotyping of HLA class I antigens and by DNA typing of the HLA class II antigens DRB1 and DQB1. In total 87 donor-recipient pairs were HLA identical with respect to HLA-A, HLA-B, HLA-DRB1 and HLA-DQB1. Owing to the improbability of finding better matched unrelated donors one antigen difference was accepted in eight pairs (HLA-A, n ¼ 2; HLA-B, n ¼ 1; HLA-DRB1, n ¼ 4; HLA-DQB1, n ¼ 1) and two antigen differences were accepted in two pairs (HLA-A+HLA-DRB1, n ¼ 1; HLA-DRB1+HLA-DQB1, n ¼ 1). In the case of two or more HLA-matched volunteer donors, final donor selection was done by additional criteria, like gender, history of pregnancies or blood transfusions, age and CMV immunization, at the transplantation unit.
Conditioning regimen
All patients received a standard conditioning regimen consisting of 12 Gy total body irradiation (TBI) and cyclophosphamide. TBI was administered in three fractions of 4 Gy from day À8 to day À6 in patients receiving a 4-day course of cyclophosphamide and from day À6 to day À4 in patients receiving a 2-day course of cyclophosphamide. Cyclophosphamide was given at a daily dose of 50 mg/kg body weight (b.w.) on days À5 to day À2. In order to reduce toxicity starting October 1997, the total dose of cyclophosphamide was reduced from 200 mg/kg b.w. (n ¼ 58) to 120 mg/kg b.w. (n ¼ 39) and it was administered at a daily dose of 60 mg/kg b.w. on day À3 and day À2. All patients received forced diuresis and dose-equivalent Mesna during the days of cyclophosphamide treatment.
In vivo T cell depletion with ATG
In 1990, we initiated a dose escalation study with antithymocyte globulin (ATG-S, Fresenius, Bad Homburg, Germany) for all patients receiving grafts from unrelated volunteer donors. 12 All eligible patients were entered in a sequential manner and after inclusion of 30 patients to each dose level, the dose was escalated to the next level. From September 1990 to September 1996, the dose was escalated from 20 mg/kg b.w. to 120 mg/kg b.w. (calculated on actual body weight). Owing to the serious adverse events at the highest dose level (two cases of intracerebral hemorrhage due to severe thrombocytopenia in non-CML patients), the dose was de-escalated to 60 mg/kg b.w. during the following year. This dose level was maintained in the following years. In all, 31 patients with CML in first chronic or accelerated phase received a total dose of ATG of less than 60 mg/kg b.w. and 66 received 60 mg/kg b.w. or more. For details see Table 2 . ATG was administered in four equivalent fractions in the morning 8 h before cyclophosphamide from day À5 to day À2 in patients receiving a 4-day course of cyclophosphamide and in three equivalent doses from day À3 to day À1 in patients receiving a 2-day course of cyclophosphamide. Initially, ATG was given without premedication over 3-4 h. Later, the infusion time was prolonged to 6-8 h and patients received 250 mg of prednisone i.v. prior to ATG infusion and 4 h later. 
GVHD prophylaxis and treatment
All patients received cyclosporine A (CSA) from day À1 to day +180 and a short-course of methotrexate (MTX) for GVHD prophylaxis. CSA was started as continuous infusion at day À1 at a dose of 5 mg/kg and reduced to 3 mg/kg at day +3. After day +3, the dose of CSA was adjusted to serum trough levels. MTX was given intravenously at a dose of 15 mg/m 2 on day +1, and at a dose of 10 mg/m 2 on days +3 and +6. In case of severe liver toxicity or mucositis, patients received leukovorin 15 mg i.v. on day +4 and +7, 24 h after the MTX injection. Acute GVHD was graded by standard criteria and treatment with high-dose prednisone (3 mg/kg b.w.) was initiated if at least grade II acute GVHD developed. In responders, prednisone was then tapered by 10% every 3 days. Nonresponders received various second-line treatments, like muromonab-CD3 (Orthoclone OKT3 s , Janssen-Cilag, Neuss, Germany) or horse-derived antilymphocyte globulin (Lymphoglobulin Merieux s , Institut Merieux Transplant, Leimen, Germany).
Supportive care
All patients were nursed in single rooms with hepa-filtered positive air pressure. Standard antibiotic prophylaxis consisted of trimethoprim-sulfametoxazole (320 mg/ 1600 mg/day) pretransplant until day À1, and after engraftment 480 mg/2400 mg twice weekly. Additionally, all patients received oral colistinsulfate and amphotericin B. Broad spectrum intravenous antibiotic treatment in combination with fluconazole (200 mg/day) was started in the event of fever according to good clinical practice procedures. For antiviral prophylaxis, patients received intravenous acyclovir (3 Â 10 mg/kg b.w./day) and polyvalent intravenous immunoglobulin (0.3 g/kg b.w.) every other week. For VOD prophylaxis, patients over the age of 40 or with a history of liver disease either received prostaglandin E1 (Prostavasine s , Schwarz-Pharma, Mannheim, Germany) at a dose of 320 mg in four equivalent doses daily or defibrotide (Prociclide s , Crinos SPA, Villaguardia, Italy) at a dose of 3200 mg in four equivalent doses daily. Only CMV-negative, leukocyte depleted and irradiated blood products were used. Weekly screening for the detection of CMV reactivation was performed in blood and urine samples by PCR and antigen assays. Gancyclovir or foscarnet treatment was initiated either prophylactically in case of prednisone treatment of acute GVHD in patients at risk (recipient or donor or both CMV positive) or as pre-emptive therapy in patients with repeated positive test results or increasing genome equivalents.
Engraftment
Engraftment is defined as the first of three consecutive days when the patient's neutrophil counts exceeded 0.5 Â 10 9 /l.
In vivo detection of ATG
We measured the concentration of rabbit IgG, the development of anti-ATG-antibodies by ELISA, and the amount of rATG by flow cytometry analysis in the serum of four patients who received 60 mg/kg b.w. (three patients) or 90 mg/kg b.w. Blood samples were taken prior to ATG injection and up to 50 days after stem cell transplantation.
Rabbit IgG and anti-rabbit IgG-antibody (ELISA). Rabbit IgG were detected by an immunoenzymatic assay. The 96-well microtiter plates were coated with 1 mg goat antirabbit IgG (Jackson Immuno Research Lab., West Grove, PA, USA). After incubation of patient sera taken at various time points, bound rabbit-IgG was detected by alkaline phosphatase-conjugated goat anti-rabbit F(ab) 2 (Immunotech, Hamburg, Germany). Absorbance was measured at 405 nm using an ELISA plate reader. To detect anti-rabbit antibodies, a similar procedure was applied except that microtiter plates were coated with diluted ATG and the extinction was revealed by peroxidase-conjugated goat anti-human IgG.
FACS analysis. The amount of free ATG in sera of patients was assessed by flow cytometry using Ficoll separated PBL. Sera were diluted 1:2 in PBS. A 50 ml volume of these dilutions were mixed with PBL and incubated for 30 min, washed twice with PBS, incubated with a FITC-conjugated goat anti-rabbit IgG antibody (Jackson Immuno Research Lab., West Grove, PA, USA), and washed with PBS. The amount of ATG in sera was estimated by plotting the medium fluorescence intensity (MedFI) from these probes against a standard curve of ATG (200 mg/ml to 0.1 mg/ml), as described. 13 
Statistical analysis
All statistical analyses were performed utilizing SPSS for Windows 10.0. (SPSS Software GmbH, Mu¨nchen, Germany). Kaplan-Meier estimates were used to calculate the probability of overall and event-free survival. Event was 
Results
ATG levels in patients sera and ATG binding to lymphocytes
Serum levels of rabbit IgG started to decrease between days 21 and 37 after transplantation, while antibodies against ATG were already found to raise between days 11 and 24 after transplantation. rATG in serum was measured by FACS analysis after blocking the Fc receptor. Levels of rATG in serum were distinguishable down to 0.8 mg/ml. Free rATG increased till day À1 up to 40 mg/ml serum and was detectable with a median half-life of 11 (range 4-15) days in concentrations above 1.5 mg/ml between day 11 and day 30 after stem cell transplantation (Table 3 ). Blood taken from a patient who engrafted 16 days after transplantation revealed an average binding of 70% of leukocytes even at this time after transplantation. Approximately 90% of CD3+, CD4+ and CD8+ lymphocytes had detectable rATG on their surface (Table 4) , and 82% of NK cells had a positive signal for rATG.
Engraftment and graft failure
All but one patient surviving more than 30 days after transplantation engrafted. The one patient who primarily did not engraft received only a total dose of 40 mg/kg b.w.
ATG during conditioning and died from infectious complications on day +42. Three more patients died from treatment-related toxicity before engraftment. The median time to engraftment was 23 days for patients receiving o60 mg/kg b.w. ATG and 20 days for patients receiving at least 60 mg/kg/ b.w. This difference was highly significant (Student's t-test: P ¼ 0.008). The median number of transfused mononuclear cells was 3. 
GVHD
Acute GVHD grade II-IV, requiring treatment, occurred in 55 patients (56.7%). Severe acute GVHD grade III-IV developed in 17 patients (17.5%). The incidence of acute GVHD grade III-IV was significantly higher in those patients receiving ATG doses less than 60 mg/kg b.w. (10.6 vs 32.5%; Student's t-test: P ¼ 0.025). Chronic GVHD occurred in 32 patients (32.9%) and was extensive in 11 patients (11.3%). Seven of the 32 patients developed chronic GVHD only after being treated for relapse with donor lymphocyte infusions (DLI). There was no significant difference for the incidence of chronic GVHD with regard to the dose of ATG used. Five patients (5.2%) died from acute GVHD, three of them had received less than 60 mg/kg b.w. of ATG. The incidence of fatal acute GVHD was 9.7% in the group of patients who received less than 60 mg/kg b.w. of ATG, and 3.0% in the group of patients who received 60 mg/kg b.w. or more of ATG. Two patients (2.1%) died from chronic GVHD.
Adverse reactions of ATG
Independent of the dose applied, adverse reactions to ATG were frequent, especially during the first day of application and have been detailed elsewhere. 14 By using a longer infusion schedule and steroid premedication, side effects could be markedly reduced although not totally avoided. As has been published, the most frequent adverse reactions included fever, chills, hemolysis, thrombocytopenia and diarrhea. 10, 11 At the highest dose level of 120 mg/kg b.w. two patients, not included in this analysis because of different underlying diseases, died from intracerebral hemorrhage possibly because of the observed profound thrombocytopenia. In CML patients, thrombocytopenia also occurred but was less severe than in patients with acute leukemia and all patients reported in this study received and tolerated the scheduled dose of ATG.
Treatment failure
Treatment-related mortality at day +100 was 12.6%. and overall mortality not related to relapse was 30.9%. Causes and time of death are detailed in Table 5 . A total of 13 patients (13.4%) relapsed and 12 of them responded to and was not correlated to the disease status at transplantation since only three of the relapsed patients were transplanted in accelerated phase.
Overall and event-free survival
With a median follow-up of 5.8. years (range 1.5-12.1 years), 5-year disease-free and overall survival for all patients was 56 and 66%, respectively. There was significant better overall survival (log-rank test: P ¼ 0.0429) and significant better event-free survival (log-rank test: P ¼ 0.0293) for patients receiving 60 mg/kg b.w. or more of ATG (Figure 1 ). In patients transplanted within 2 years of diagnosis,event-free and overall survival were 72 and 82%, respectively. In this subgroup the differences with respect to the ATG dose used were even more pronounced. Patients receiving 60 mg or more of ATG had a 5-year disease-free and overall survival of 83 and 90%, respectively and for patients receiving less than 60 mg the survival rates were 32 and 55%, respectively ( Figure 2 ). These differences could not be observed in the subgroup of patients transplanted later than 2 years after diagnosis (data not shown).
Univariate analysis
For overall and event-free survival, the following risk factors were analyzed by log-rank test: patient age (o45 vs X 45 years), disease status at transplantation (first chronic phase vs accelerated disease), time to transplantation (o2 vs X2 years), recipient-donor sex combination (male recipient/female donor vs all other combinations), HLA mismatch, graft MNC number (o3 Â 10 8 vs X3 10 8 kg b.w), the occurrence of acute GVHD, grade II-IV, the occurrence of chronic GVHD, the occurrence of relapse (only for overall survival), CMV reactivation (defined by PCR positivity or CMV antigenemia), CMV status of recipient and donor, dose of ATG (o60 vs X60 mg/kg b.w.), dose of cyclophosphamide and transplantation period (1990-1996 vs 1997-2001 ). Significant (Po0.05) factors and additional factors (Po0.2) selected for multivariate analysis for overall and event-free survival are shown in Table 6 . The same analysis just omitting the parameter time to transplantation was performed for the subgroup of patients transplanted within 2 years after diagnosis. The results are depicted in Table 7 . Whereas univariate analysis for all patients revealed the occurrence of acute GVHD, the higher dose of cyclophosphamide, disease status at transplantation and patient's age of at least 45 years as the most important adverse factors for overall survival, the subgroup analysis for patients transplanted within 2 years of diagnosis found disease status at transplantation and o60 mg/kg b.w. of ATG as the only significant adverse factors for overall survival. For eventfree survival time to transplantation, disease status at transplantation, a lower dose of ATG and a dose of 200 mg/kg b.w. of cyclophosphamide were significant risk factors for an unfavorable outcome in the whole group, whereas in the subgroup of patients transplanted within 2 years of diagnosis low-dose ATG and disease status at transplantation again proved to be the only significant risk factors. In the subgroup of patients transplanted later than Table 5 Causes of nonrelapse-related death n=30 Day of death   5  Acute GVHD  +37, +39, +42, +47, +77  2  Chronic GVHD  +372; +372  1  Hemorrhage  +123  19  Infections  2  Aspergillosis  +23, +148  1  CMV-pneumonia  +269  6  Pneumonia  (bacterial, viral)   +23, +108, +530, +545,  +663; +1479  6  Sepsis  +17, +23, +112, +119,  +192, +1325  2  Multiorgan failure  +77, +195  2  Toxoplasmosis  +42, +65  1 Veno-occlusive disease +12 1 Secondary malignancy +780 1 Unknown +762 Figure 1 Kaplan-Meier estimates of (a) overall and (b) event-free survival of all CML patients included in the study. The solid line indicates patients who received 60 mg/kg of ATG or more, as compared to those who received less than 60 mg/kg of ATG (broken line). The statistical significance, as indicated, has been calculated by log-rank test.
CAUSE of death
2 years after diagnosis, the most important risk factors were the occurrence of acute GVHD, lower graft cell numbers and a female donor for a male recipient (data not shown).
Cox regression analysis
The most important independent risk factors for unfavorable outcome with respect to overall survival of the whole group were the occurrence of acute GVHD, patient's age of at least 45 years, graft cell numbers of less than 3.0 Â 10 8 / kg. b.w. of the recipient and a time interval of more than 2 years from diagnosis to transplantation (Table 8 ). Time to transplantation was also a significant factor influencing event-free survival, as was dose of cyclophosphamide, a female donor for a male recipient and less than 60 mg/kg of ATG during conditioning. Owing to the relatively small number of patients and a strong correlation between dose of ATG, dose of cyclophosphamide and the transplantation period in the subgroup of patients transplanted within 2 years after diagnosis, Cox regression analysis was not performed for this subgroup.
Discussion
Many groups have reported that the interval between diagnosis and transplantation is a very important factor for the outcome of allogeneic stem cell transplantation in patients with CML. 3, [15] [16] [17] Our data further confirm these observations. The Cox regression analysis revealed that the risk of an unfavorable outcome was more than doubled in patients transplanted later than 2 years after diagnosis. Although the overall incidence of acute and chronic GVHD was not different in patients transplanted within 2 years of diagnosis or later, the severity of GVHD was enhanced in patients transplanted late during the disease, thus resulting in a doubled rate of nonrelapse-related mortality. In addition, there was also a higher percentage of relapses in these patients.
Our study also confirms and extends the data of other groups 10, 11 that by the inclusion of ATG into the preparative regimen the incidence and, especially, the severity of acute GVHD can be reduced. Severe acute GVHD grade III-IV developed in 17.5% of our patients. This incidence is much lower than those reported from other studies (430%), which did not include ATG in the preparative regimen, but used standard GVHD prophylaxis mainly with CSA and MTX. 3, 18 However, this benefit seems to be restricted to, and then being even more pronounced in, those patients who received at least 60 mg/kg b.w. of ATG.
Furthermore, the low incidence of graft failure is a very important finding of our study which favorably compares to the results of up to 16% of graft failure reported in studies not incorporating ATG into the preparative regimen. The statistical significance, as indicated, has been calculated by log-rank test. Table 6 Univariate analysis for overall and event-free survival for all patients (asterixes indicate significant factors)
Factor
Overall survival Therefore, the dose of ATG seems to be a critical factor, which so far has not been analyzed systematically for patients with CML. After a median follow-up of 5.8 years, the Kaplan-Meier estimate revealed significant differences for the probability of event-free (68 vs 39%) and overall survival (72 vs 52%) in favor of ATG doses of at least 60 mg/kg b.w. In multivariate analysis of overall survival, the effect of the ATG dose used was hidden by other important prognostic factors like time interval between diagnosis and transplantation or graft mononuclear cell number. However, Cox regression analysis of event-free survival proved that inadequate dosing of ATG represents an independent risk factor. In patients receiving less than 60 mg/kg b.w. of ATG, the risk of relapse or death was more than doubled. Additionally, we did a subgroup analysis for those patients transplanted within 2 years of diagnosis. In univariate analysis with Kaplan-Meier estimates, the effects of the ATG dose were highly significant for event-free and overall survival giving excellent survival rates (ES 88%, OS 90%) with the higher ATG dose used. To the best of our knowledge, similar survival rates have not been reported for CML patients transplanted from unrelated volunteer donors so far. Interestingly, these differences could not be observed in the subgroup of patients transplanted later during their disease, indicating that the risk and severity of acute GVHD may be increasing and more difficult to control by duration of the disease.
The incidence of chronic GVHD was with 32.9 and 11.3% extensive similar to the incidences reported from studies incorporating ATG, 10 but lower than those reported by other investigators using standard GVHD prophylaxis (53-67%). 2, 3, 18 Other strategies to reduce the incidence of acute GVHD in URD-BMT including T cell depletion of the graft with the T10B9 monoclonal antibody 5 or ex vivo or in vivo T cell depletion with Campath-1M or -1G also resulted in less acute GVHD but resulted in graft failure rates up to 16% at 1 year 19 and higher relapse rates. 20 By contrast, in our study, we only observed one case of graft failure. Indeed, T cell depletion of the graft appeared to be a negative predictive factor for event-free survival in a survey from the European Group for Blood and Marrow Tranplantation. 21 ATG has been used in marrow transplantation since nearly 30 years. In the early years, no benefit was reported in canine studies or in matched sibling transplantations for patients with leukemia. 22, 23 However, there are different preparations of anti-T lymphocyte globulins from various animal sources available. The specificity of these different preparations is not comparable. The ATG used in our study is derived from rabbits immunized with the T lymphoblastic leukemic Jurkat cell line. Since the immunophenotype of this cell line differs from thymocytes, the activity of the purified immunoglobulin is probably not comparable to the activity of preparations that are derived from animals immunized with fetal thymic tissue. These preparations may have a much broader spectrum of activity, thus possibly resulting in higher rates of graft failures, relapses and infections. In particular, alemtuzumab has been reported to be associated with an exceptionally high risk of CMV reactivation (85%), whereas in our study the rate of CMV reactivations (27%; Table 1 ) was comparable to preparative regimens without in vivo T cell depletion. 24 In addition, as mentioned above, the dose of ATG seems to be a critical factor. In an earlier study, we observed a higher relapse rate in high-risk patients receiving 80 mg/kg b.w. or more of ATG. 25 In the current study with low-risk CML patients, we could not observe similar results regarding the relapse rates. Nevertheless a dose of 60 mg/kg b.w. seems to be sufficient to ensure engraftment and reduce acute GVHD to an acceptable level in unrelated transplants for CML.
ATG is expected to enhance T cell depletion in combination with TBI and cyclophosphamide in recipients of allogeneic grafts prior to stem cell transplantation and also to deplete in vivo the donor T cell inoculum. As free rATG is still detectable up to 30 days after infusion, it might further contribute to the reduction of acute GVHD. However, our data provide evidence that recovery of T cells occurs even in the presence of measurable rATG serum levels. Thus it seems questionable if ATG still remains functional at these time points. The mechanism(s) by which ATG applied during the preparative regimen reduces the incidence of acute GVHD, therefore, remains to be determined.
In conclusion, allogeneic BMT from unrelated volunteer donors offers an excellent treatment option to patients with chronic phase CML, provided it is performed early during disease and a sufficient amount of ATG is included in the preparative regimen. The notion that it may safely be delayed for first conducting a trial with interferon-a or imatinib mesylate is not supported by our data. 
